Ritlecitinib: Unveiling Hair Regrowth for Alopecia Areata

    September 2024 in “ Annals of Medicine and Surgery ”
    Nawal Khaliq, Rumaisa Riaz, Mushkbar Khan … Aymar Akilimali
    Studysummary In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Related research 3

    1. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    2. GainmoreTM M: An Oral Supplementation in Men with Androgenic Alopecia for Reduction in Hair Loss and New Hair Growth Europe PMC (PubMed Central) · 2015
    3. Overview of Alopecia Areata ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2013